Organon

Organon, a pharmaceutical preparation manufacturing company based in the US, reported a total of approximately 1.07 billion kg CO2e in Scope 1, 2, and 3 greenhouse gas emissions for the year 2022.

Key Emissions Data (kg CO2e):

• 2022:

  • Scope 1: Approximately 658,000 kg CO2e
  • Scope 2 (Market-based): Approximately 30,784,000 kg CO2e
  • Scope 3: Approximately 1,029,000,000 kg CO2e (with purchased goods and services being the largest contributor at approximately 765,000,000 kg CO2e).
  • Total Emissions: Approximately 1,066,922,000 kg CO2e.

• 2021:

  • Scope 1: Approximately 734,000 kg CO2e
  • Scope 2 (Market-based): Approximately 31,653,000 kg CO2e
  • Scope 3 emissions data was not fully disclosed for 2021.
  • Total Emissions: Not provided as a single figure.

• 2020:

  • Scope 1: Approximately 902,000 kg CO2e
  • Scope 2 (Market-based): Approximately 32,701,000 kg CO2e
  • Scope 3 emissions data was not fully disclosed for 2020.
  • Total Emissions: Not provided as a single figure.

Climate Commitments and Reduction Targets:

Organon has established near-term reduction targets. The company aims to reduce its Scope 1 and 2 greenhouse gas emissions by more than 25% from 2020 levels by the year 2025. This target is an absolute reduction commitment.